Product
Cosentyx
Aliases
Secukinumab
5 clinical trials
4 indications
Indication
PsoriasisIndication
HealthyIndication
Inflammatory DiseaseIndication
Autoimmune DiseasesClinical trial
A Randomized, Double-blinded, Single-dose, 3-arms Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT2306 Injection vs Secukinumab Injection (Cosentyx®) in Healthy Chinese Male SubjectsStatus: Completed, Estimated PCD: 2023-05-03
Clinical trial
A Phase 1, Single Center, Randomized, Controlled Platform Study Validating the Use of Candin as a Challenge Agent in Healthy Volunteers or Patients Given Concomitant Approved InterventionsStatus: Completed, Estimated PCD: 2022-11-02
Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2306 With Cosentyx® in Patients With Moderate to Severe Plaque PsoriasisStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
Personalized Targeted Therapies in Inflammatory Complex Multi Organ DiseaseStatus: Recruiting, Estimated PCD: 2025-11-01